Literature DB >> 20527670

Bosentan treatment unable to alter the progression of interstitial lung disease in patients with SSc.

Katrin Legg.   

Abstract

Entities:  

Year:  2010        PMID： 20527670     DOI： 10.1038/nrrheum.2010.74

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

Authors:  J R Seibold; C P Denton; D E Furst; L Guillevin; L J Rubin; A Wells; M Matucci Cerinic; G Riemekasten; P Emery; H Chadha-Boreham; P Charef; S Roux; C M Black
Journal:  Arthritis Rheum       Date:  2010-07
  1 in total
  1 in total

Review 1.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.